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ABSTRACT 
Sarcoidosis is a granulomatous disease that usually involves the lungs and is 
diagnosed in between 10 and 35 per 1000 people in the U.S.  Sarcoidosis is characterized by 
a highly variable disease presentation and course where some individuals spontaneously 
resolve and others progress to end-stage fibrosis and death.  The causes of sarcoidosis are 
largely unknown, but development is believed to be a result of genetic factors affecting the 
immune response combined with an environmental trigger.  Tobacco smoking is the 
exposure most strongly associated with sarcoidosis, but not as a risk factor.  Studies have 
repeatedly shown that smoking is negatively associated with disease.  However, few studies 
have examined the relationship between smoking and the severity of the disease.  The goal of 
this study was to describe a sarcoidosis clinical population and to examine the relationship 
between cigarette smoking and disease severity.  The study utilized a population of 
sarcoidosis patients from National Jewish Health.  The population was described by a 
number of demographic and clinical characteristics collected from questionnaire, physical 
exam and electronic medical record. The relationship between smoking status and severity of 
disease was assessed using two previously-developed severity scoring systems, the Wasfi 
severity score and the Pulmonary Severity Scoring Index (PSSI).  The Wasfi score 
technically consists of 2 scores: one based on spirometry values and the other based on 
pulmonary function test (PFT) values.  Linear regression and ordinal logistic regression were 
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used to test for association between smoking and the Wasfi severity score and the PSSI score, 
respectively.  Mean differences of 0.179 (95% CI: -0.330,0.688; p-value: 0.4899) and 0.414 
(95% CI: -0.372, 1.200; p-value: 0.2992) were found for the relationship between smoking 
status and severity determined by the Wasfi score based on spirometry and the Wasfi score 
based on PFTs, respectively.  However, neither of these were statistically significant.  
Likewise, the association between smoking status and severity based on the PSSI (OR: 
1.912; 95% CI: 0.829, 4.410; p-value: 0.1290) was not statistically significant.  While this 
study is the largest clinical population studied for associations between cigarette smoking and 
severity, we cannot rule out important contributions of cigarette smoking to disease severity.  
The primary limitation of our study and all others assessing disease severity is the cross-
sectional nature of the severity scoring; longitudinal sampling of cases is required to both 
better define disease severity and identify patient characteristics and exposures associated 
with more severe forms of disease.      
The form and content of this abstract are approved. I recommend its publication. 





TABLE OF CONTENTS 
CHAPTER 
I. INTRODUCTION…………………………………………………………….1   
Physiology & Clinical Presentation…………………………………………...β 
Risk Factors & Known Associations………………………………………….4 
 Genetics………………………………………………………………..5 
 Environmental Exposures……………………………………………..6 
 Tobacco Smoke………………………………………………………..7 
Severity Scores………………………………………………………………...9 
II.  SPECIFIC AIMS & STUDY HYPOTHESES………………………………14 
III.  METHODS…………………………………………………………………..17 
Subjects………………………………………………………………………17 









  A. Associations of Smoking Status and Individual Component Variables of Each  
       Severity Score…………………………………………………………………….45 





 Sarcoidosis is a chronic disease of unknown cause that can result in severe and 
sometimes life-threatening outcomes.  It is estimated to affect between 10 and 35 per 100,000 
people in the United States.  Therefore, at least 110,000 people in the country have this 
disease, but it is probable that the actual number is much greater, because many people are 
likely undiagnosed or misdiagnosed1.  Sarcoidosis causes granulomas to form in various 
organs of the body, particularly the lungs.  The exact etiology is unknown at this point.  The 
prevailing hypothesis is that the disease is a result of the interaction of genetic and 
environmental factors.  It seems that the body responds inappropriately to an environmental 
exposure due to genetic factors that influence the cells of the immune system. Granulomas 
form when the cells of the immune system fail to dissipate from an inflammatory response 
and cluster together2.  Figure 1 displays a very general model for how sarcoidosis results 
from an interaction of genetics and environmental exposures. 
 




Physiology & Clinical Presentation 
Under normal circumstances, the inflammatory response is triggered by macrophages 
that engulf foreign antigens and present them on their surfaces using the Human Leukocyte 
Antigen (HLA) Class II.  The macrophages are known as antigen-presenting cells (APCs), 
and they interact with CD4+ T cells, which differentiate into Th1-like cells that produce 
interleukin-2 and interferon- .  These cytokines then recruit more immune cells to the 
location to fight the invading organisms.  The efficiency of antigen processing, antigen 
presentation, and cytokine release is probably under genetic control.  After an adequate 
response that neutralizes the threat, the immune cells dissipate from the area.  However, in 
the case of sarcoidosis, the inflammatory cells do not dissipate.  Cells proliferate, cytokines 
and chemokines continue to be produced and released, and eventually the cells cluster 
together to form granulomas2.   
Granulomas can form in any organ, but they usually are found in the lungs, lymph 
nodes, skin, or eyes.  The lungs are the organs most commonly affected by sarcoidosis.  Lung 
involvement is found in about 90% of people with sarcoidosis.  The granulomas can be fairly 
benign, and many people remain asymptomatic.  However, the granulomas can interfere with 
the proper functioning of the organs.  This interference is what leads to symptom 
manifestation.  For instance, people with lung involvement can experience breathing 
difficulty, cough, and chest discomfort.  The disease can be life-threatening if the granulomas 
cause severe fibrosis, resulting in very poor lung function.  Eye and skin involvement are 
also quite common, accounting for 25% and 20-50% of sarcoidosis cases, respectively.  
Cardiac and neurological involvement are rarer presentations of the disease, but they can be 
especially dangerous and are the most likely to lead to fatalities. Many cases of liver and 
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spleen involvement have been reported, too.  A significant proportion of people with 
sarcoidosis have more than one organ system that is affected3. 
In addition to the organ-specific symptoms, individuals with sarcoidosis often 
experience systemic symptoms, including fatigue, night sweats, and loss of weight.  About 
10% of people with sarcoidosis have an acute form of the disease known as Löfgren’s 
Syndrome.  This presents with arthritis, erythema nodosum, and bilateral hilar adenopathy.  
This form of sarcoidosis normally has better outcomes than the chronic form.  It is also 
usually easier to diagnose, because the presentation is very characteristic of this condition4.  
The chronic form of sarcoidosis can be challenging to definitively diagnose.  It is known as a 
diagnosis of exclusion; once all other potential conditions have been ruled out, a diagnosis of 
sarcoidosis can be made.  In many cases, sarcoidosis is first suspected incidentally after 
examining an abnormal chest X-ray (CXR).  In order to confirm sarcoidosis, a biopsy of the 
affected tissue must be taken and examined for non-caseating granulomas.  The biopsies are 
normally taken from the lungs, mediastinal lymph nodes, or skin.  The disease can be tracked 
clinically by examining CXRs, CT scans, pulmonary function tests (PFTs), echocardiograms 
(ECG), serum calcium levels, renal function tests, and others4.  The disease is normally 
treated by suppressing the immune response or managing specific symptoms.  
Corticosteroids, such as prednisone, and other immune suppressors, such as Methotrexate, 
are common treatments that suppress the immune response which caused the granuloma 
formation.  These drugs do not act as a cure for the disease but help to slow progression and 
alleviate symptoms.  Some individuals do not require treatment; in fact, many go into 




Risk Factors & Known Associations 
 Sarcoidosis affects people of all races and ethnicities, and it can present at almost any 
age.  However, some groups are at greater risk of developing the disease than others.  For 
instance, women have a slightly higher incidence of disease than men.  Also, in the United 
States, African Americans have a substantially greater incidence of sarcoidosis than 
Caucasians.  Sarcoidosis also tends to be more severe in that population.  The incidence rate 
in African American men is about 29.8 per 100,000 people and 39.1 per 100,000 people in 
African American women.  In comparison, the rate is 9.6 per 100,000 in Caucasian men and 
12.1 per 100,000 in Caucasian women.  Incidence differs throughout the world, affecting 
some populations more than others or at different rates.  These differences across countries is 
likely due to a number of factors, such as differences in environmental exposures, 
surveillance methods, and predisposing HLA alleles and other genetic factors.  The highest 
annual incidence to be reported is in northern European countries with a range of 5-40 cases 
per 100,000 people.  On the other side of the spectrum, Japan only reports about 1-2 cases 
per 100,0005.   
 Another risk factor associated with the disease is a person’s age.  Sarcoidosis can 
technically present at any time, but it usually develops before 50 years of age, with the 
incidence peaking between 20 and 40 years old.  Other genetic and environmental exposure 
risk factors have been explored in studies, but most potential associations are rather 
speculative at this point due to low-powered studies and/or results that have not been 




 The region of the genome that has been shown to be most highly associated with the 
disease is the HLA gene region.  This region is responsible for producing the human 
leukocyte antigens.  The purpose of these antigens is to distinguish between self and foreign 
proteins, and ultimately initiate an immune response when a foreign particle is encountered.  
Class I HLA-B8 was one of the first genes to be found to be associated with sarcoidosis.  
Since then, it has been shown to be strongly associated with specifically the less common 
acute onset of the disease (Löfgren’s Syndrome).  Further investigation revealed that the 
HLA class II antigen genes have consistently been shown to be strongly associated with 
sarcoidosis.  Specifically, the HLA-DRB1 and DQB1 alleles have been the subjects of such 
studies6,7. 
 The antigen-binding properties of the HLA class II peptide-binding groove are 
determined by polymorphic amino acid residues. These residues form pockets in the groove, 
interacting with the antigenic peptide side chains. A recent study suggests that pocket 9 of 
HLA-DQ and pocket 4 of HLA-DR are the most important regions involved in the 
association with sarcoidosis.  Recent reports suggest that these genes relate to the phenotype 
of the disease rather than the actual susceptibility of disease.  For example, HLA-
DQB1*0201 and HLA-DRB1*0301 are strongly associated with acute disease and a good 
prognosis6,7. 
 Another gene that has been consistently shown to be associated with sarcoidosis is the 
BTNL2 gene, located within the MHC class II region of chromosome 6.  It likely acts as a 
negative T-cell costimulatory molecule.  However, it is not known how an aberrant form of 
this molecule would lead to the development of the disease8.  S veral other genes have been 
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indicated by studies, including genes for TNF-α, interferon- , and chemokine receptors.  
However, these have not been definitively established as risk factors, because the studies 
have been small, and the results have not been replicated9,10. 
 More studies have shown the importance of genetic risk factors for sarcoidosis.  Of 
people with sarcoidosis, it has been shown to be familial in 9.6%, 3.6%, and 4.3% in those of 
Irish, Finnish, and Japanese descent respectively11,12.  These values are significantly higher 
than that of the general population.  A study known as ACCESS (A Case Control Etiologic 
Study of Sarcoidosis) showed that the familial relative risk of sarcoidosis was 2.8 in African 
Americans (AAs) and 1.8 in Non-Hispanic Whites (NHWs)13.  The differences in these 
values are likely mostly due to differences in genetic susceptibility based on varied genetic 
backgrounds.   
Environmental Exposures 
 Very few environmental exposures have been shown to be strongly and consistently 
associated with sarcoidosis.  Tobacco smoke is perhaps the exposure with the most evidence 
to support such an association.  Several studies have indicated a negative association between 
cigarette smoking and sarcoidosis in U.S. populations.  It is thought that the nicotine in 
cigarettes may suppress the immune system, preventing the accumulation of cells and, thus, 
granulomas14.  Other exposures have been hypothesized as possible triggers of the disease.  
Certain bacterial or viral infections (i.e. Mycobacterium tuberculosis), organic dusts, 
aerosolized chemicals are a few examples.  Some studies have specifically examined 
associations between disease and occupations.  Using the ACCESS population14, positive 
associations with sarcoidosis were found among those exposed to musty occupational 
conditions, insecticides at work, raising birds, and other mostly workplace exposures.  Cat 
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exposure, using foam pillows, and working as a data processor are examples of exposures 
that were negatively associated with disease.  However, most of the associations that came 
out of this study have not been replicated, and there are many potentially confounding factors 
that were not considered14. 
 Aerosolized exposures have been the primary focus of these studies because of the 
organ systems that are usually involved in sarcoidosis.  Airborne particles are most likely to 
affect the lungs, skin, and eyes.  It is thought that sarcoidosis is triggered by a foreign antigen 
that is introduced into the body, primarily through one of these organs14. 
Tobacco Smoke 
Tobacco smoking has been repeatedly shown to be negatively associated with 
sarcoidosis.  ACCESS—one of the largest sarcoidosis studies to date—examined many 
environmental and occupational exposures and their relationship to the disease.  The study 
found that in simple analysis, cigarette smoking status (ever/never) was significantly 
associated with the disease.  A person with sarcoidosis was 0.62 (0.50-0.77) times as likely to 
be an “ever smoker” compared to a normal control.  This statistic had a p-value of less than 
0.001.  When considered in multiple logistic regression, taking into account several possible 
confounding variables, the odds ratio was almost identical (0.65; 0.51-0.81) and still 
significant (p-value <0.001)14.  Another study15 found similar results.  Using patient records 
and results from the General Household Surveys, the researchers concluded that smoking 
was significantly less common amongst sarcoidosis cases versus the general population.  
This study also found that the relative risk among former smokers compared to current 
smokers was about the same15.  Furthermore, a third study16 conducted in France came to the 
same conclusion.  This study also determined that the number of cigarettes smoked per day 
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did not have a significant impact on the results.  However, the researchers admitted to a low 
amount of power for that particular analysis16.  Finally, a matched case-control study also 
found that there was a significant negative association between smoking and sarcoidosis17.  
There have been a couple of studies that had different conclusions, however.  For instance, a 
case-control study failed to find a significant association between smoking and disease18, and 
another study actually found an increased prevalence of smoking in most age groups of 
people with sarcoidosis compared to the general population19.  However, this study was 
conducted in Japan on a very different population than most of the other sarcoidosis studies.  
Overall, the evidence at this point suggests that cigarette smoking is negatively associated 
with sarcoidosis. 
Some studies have investigated the physiology behind the negative association of 
smoking and sarcoidosis.  Most have focused on how tobacco smoke affects the immunity-
based cells within the lungs.  For instance, the previously mentioned French study16
suggested that the protective nature of cigarette smoke with regards to sarcoidosis could be a 
result of changes in the balance of immune and inflammatory cells in the lungs caused by 
exposure to tobacco.  Their study found an abnormally small amount of macrophages in the 
brochoalveolar lavage (BAL) samples that were obtained16.  Another study20 examined the 
effects of cigarette-smoking on CD8+ T lymphocytes.  The researchers were primarily 
focused on chronic obstructive bronchitis.  However, the study does provide insight in how 
smoking can affect CD8+ T cells, along with its ratio to CD4+ T cells and the cytokines 
produced by those cells20.   
Another study21 asked a similar question.  Like several other studies, this study 
examined the relationship of cigarette smoking and sarcoidosis, but they also investigated the 
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effects of smoking on the severity of the disease.  The researchers concluded that the 
prevalence of smoking was lower in subjects with sarcoidosis versus their control group.  
However, using a combination of BAL samples, serum angiotensin converting enzyme 
(ACE) levels, PFTs, and radiography; the researchers concluded there was no significant 
difference in severity among smoking and non-smoking cases.  However, a few of the 
measurements obtained were associated with smoking.  For instance, there was increased 
ACE activity in smokers.  Also, a greater number of CD8+ lymphocytes were obtained from 
the BAL in smokers, and this led to a lower CD4+:CD8+ ratio21.  And like study in France16, 
there were fewer macrophages in the BAL samples in smoking cases than in smoking 
controls16,21. 
Severity Scores 
 The most common system used for classifying pulmonary sarcoidosis is chest X-ray 
scadding stage.  This system has been used for over 50 years.  A person with pulmonary 
sarcoidosis is classified into one of five categories (stage 0-4) based on the appearance of 
his/her chest X-ray (CXR).  Stage 0 indicates that there are no visible abnormalities 
associated with sarcoidosis.  Stage 1 means that there is hilar lymphadenopathy consistent 
with sarcoidosis.  Stage 2 indicates lymphadenopathy along with lung parenchyma infiltrates; 
whereas, stage 3 means that there is evidence of lung infiltrates without lymphadenopathy.  
Finally, stage 4 indicates actual fibrosis (scarring) of the lung tissue4.  This system is not a 
progressive system or even a severity ranking system.  People with sarcoidosis do not 
necessarily go through each stage in order or even at all.  Furthermore, the stages do not 
indicate an objective ranking of severity.  Although stage 0 is usually considered to be the 
mildest and stage 4 is the most severe, these stages are not necessarily arranged sequentially 
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in order of severity.  Moreover, this system is considered by many clinicians to be outdated 
and not predictive of clinical manifestation or severity22.   
 Many clinicians consider lung function to be a much better representation of disease 
severity.  It is a more direct measure of the symptoms than an X-ray.  To address this, 
quantitative severity scoring systems have been developed to include clinical measurements 
such as Forced Vital Capacity (FVC), Forced Expiratory Volume within 1 second (FEV1), 
and other pulmonary function values.  
 This study will be using multiple severity scoring systems.  One system was 
developed by Wasfi and colleagues and, from this point, will be referred to as the Wasfi 
score.  The researchers’ goal was to develop a system that accounted for a variety of disease 
factors at a single point in time—specifically accounting for multiple organ involvement.  Up 
to that point, sarcoidosis severity classification was primarily focused on pulmonary 
involvement only by examining abnormal lung function and radiography22. 
 The researchers accomplished this using a group of 104 patients recruited through 
National Jewish Health’s (NJH’s) clinic.  A variety of clinical and demographic data was 
collected on each patient to represent “the extent of pulmonary disease, the extent of 
extrapulmonary involvement, patient demographic variables, disease duration, and 
treatment”.  Each patient’s clinical history and relevant data was reviewed by three NJH 
panel experts and individually scored using a visual analog scale (VAS) that ranged from 0 to 
10, with 0 indicating an asymptomatic individual and 10 defined as the presence of severe 
and/or life-threatening end-organ dysfunction.  From this assessment, a severity model was 
devised using univariate analyses to compare individual clinical variables and the mean 
severity scores of the panel.  Variables with a p-value ≤ 0.β5 remained for evaluation in the 
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multivariable model.  Backward multiple linear regression derived the final model, keeping 
in variables that had p-values of 0.15 or smaller.  A second model was also developed in the 
same way, but it only included variables that would likely be available for all patients.  
Specifically, this second model only contained values from spirometry rather than full 
pulmonary function tests.  The final models using both methods were quite similar.  This 
study will utilize both models22. 
 The Wasfi study found that the most important predictors of severity were cardiac 
involvement, neurological involvement, the use of non-corticosteroid immunosuppressive 
agents, and DLCO% predicted.  Other variables were also significant to include in the model.  
The final model (referred to as Wasfi [DLCO]) is as follows: 
 
Severity score = 11.47 +3.51(C) +2.27(N) +1.41(IS) -0.033(DLCO%) -0.047(FEV1/ VC) 
+1.23(AA) -0.027(FVC% predicted) +0.52(skin); 
 
“where C=1 if there is cardiac involvement, 0 if not; N=1 if there is neurological 
involvement, 0 if not; IS=1 if receiving non-corticosteroid immunosuppression therapy, 0 if 
not; AA=1 if the subject is African American, 0 if not; and skin=1 if there was skin 
involvement, 0 if not.” 
 The second model that was derived from spirometric measures is referred to as Wasfi 
(Spirometry) and is obtained through the following equation: 
 




 Another scoring system that will be used was developed by Hamzeh et al.   The 
purpose of this severity score—known as Pulmonary Sarcoidosis Scoring Index (PSSI)—was 
to serve as a simple assessment that could be widely used to objectively classify pulmonary 
sarcoidosis23.  This differs from Wasfi’s objective of being able to assess the multi-organ 
aspect of the disease.  PSSI evaluates strictly pulmonary disease.   
 This scoring system utilizes clinical values from spirometry, DLCO, and radiography.  
These clinical features were first individually scored; then the scores were combined to give 
a final assessment score.  Using information from previous studies, the researchers 
determined that the most useful clinical measures to use in this scoring system were DLCO, 
FEV1/FVC ratio, FVC, and scadding stage.  Specific cutoff points were assigned to the 
pulmonary function measures.  The ranges between these cutoff points were given a 
designated score of 0, 1, or 2.  Similarly, scadding stage was further subdivided into 
categories that also received the same type of scoring.  The cutoffs and scores attached to 
them are shown in Table 1.  The final PSSI score is the sum of each of the 4 categories.  
Therefore, the PSSI is an ordinal score that ranges from 0 to 7.23 
Table 1.  Criteria for calculating PSSI. 
PSSI    
Clinical Parameter Points 
 0 1 2 
CXR Scadding 
Stage 
0 / I II / III IV  
DLCO % predicted ≥ 80% 60-79% ≤ 59% 
FVC % predicted ≥ 80% 60-79% ≤ 59% 
FEV1/FVC ratio ≥ 70% < 70%  
 
 The score was first validated using 92 NJH patients that had a diagnosis of 
sarcoidosis (according to the ATS/ERS/WASOG sarcoidosis statement definition).  Each 
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person was given a PSSI score according the criteria listed above.  These scores were then 
compared to cardiopulmonary exercise test (CPET) parameters and the Oberstein CT score.  
The Oberstein score assigns a lung “anomaly” score based on four patterns of parenchymal 
involvement along with pleural and lymph node abnormalities.  The parenchymal patterns 
include thickening/irregularities in the bronchovascular bundle, parenchymal consolidation, 
intra-parenchymal nodules, and septal and non-septal lines.  These features were used to 
validate the PSSI score.  After this validation, the researchers utilized a replication cohort 
consisting of the same cohort used by Wasfi’s team, limited to those patients with pulmonary 





SPECIFIC AIMS & STUDY HYPOTHESES 
 Aim 1 of this study defines the clinical population of sarcoidosis using descriptive 
epidemiological methods.  This is a new study population; therefore, performing an analysis 
to determine the underlying demographic distribution is appropriate.  The population consists 
of a large portion of sarcoidosis patients from National Jewish Health.  The population was 
described by numerous relevant variables, including age, gender, scadding stage, and therapy 
use. 
 Aim 2 examined the association between tobacco smoke and severity of sarcoidosis. 
Severity of disease was determined using a combination of two methods of classifying 
disease.   This aim analyzed smoking status as it relates to severity of sarcoidosis 
presentation, using the Wasfi severity score and PSSI.    
 The underlying assumption for this question is that no association exists between 
smoking status and disease severity.  However, given the known physiological effects of 
tobacco smoke and its association with sarcoidosis, it is reasonable to expect that an 
association may exist.  This study was designed to investigate if there is an association, either 
positive or negative.  The study’s hypothesis can take two forms.  First, it could be 
hypothesized that smoking is negatively associated with severity, just as its negatively 
associated with disease.  The immune suppressive effects of nicotine may decrease the 
damaging effects of sarcoidosis, minimizing severity.  However, the opposite could also be 
hypothesized.  Tobacco smoking causes a number of long-term detrimental physiological 
changes to the body.  These damages may compound the harmful effects of sarcoidosis, 
therefore increasing severity. 
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 Figure 2 is a conceptual model of the potential pathways that lead from cigarette 
smoking to disease severity.  There are two pathways presented to provide possible 
explanations for both hypothesized outcomes.  The first is the pathway leading from the 
exposure (cigarette smoking) to the outcome (level of severity) of decreased severity.  The 
second model suggests the opposite effect.  In between the exposure and outcome is the 
biological mechanism of how the exposure may be effecting the outcome. 
Included in this model are some other potentially relevant variables—some of which 
are used in the actual analyses.  Age, gender, race, and socioeconomic status (SES) could all 
be potential confounders, as they may be associated with the exposure and outcome.  At this 
point, not enough research has been conducted to state that those factors are actually 
associated with disease severity, but it is important to acknowledge the possibility.   
 The amount of time that has elapsed since diagnosis is also included in the model.  
This study is cross-sectional, making this time variable potentially very important in 
correctly assessing associations with sarcoidosis.  Likely, this variable is only associated with 
the outcome and, therefore, would be classified as a precision variable.  Therapy or treatment 
is also included in the model.  Treatment almost certainly affects disease severity, and 





Figure 2. Conceptual model of the hypothesized mechanisms of how cigarette smoking is 







This study utilized subjects from the National Jewish Health biobank and sarcoidosis 
biorepository.  Basically all NJH patients are asked to be a part of the biobank.  Patients give 
consent to have some of their blood samples stored in the biobank.  Sarcoidosis patients in 
the biobank were included in this study.  The list was comprised of sarcoidosis patients that 
consented to be a part of the NJH biobank between 2008 and 2011.  The patients were added 
to the sarcoidosis biorepository database and marked as a biobank specimen.   
The sarcoidosis biorepository is a list of NJH sarcoidosis patients that consented to 
provide blood samples specifically for the biorepository.  The biorepository was developed to 
store blood samples for use in future sarcoidosis research studies.  Any NJH patient with 
confirmed or suspected sarcoidosis is eligible to be enrolled.  They are recruited in the clinic 
by physicians or researchers.  If a subject consents, he/she fills out a questionnaire, gives a 
blood sample, and his/her information is put into the biorepository database.  The pertinent 
information is obtained from the questionnaire and/or the electronic medical records.  The 
biorepository was started in 2010.  Recruitment is ongoing.  At the time of this study, there 
were 765 subjects in the biorepository database.  Of those, 68 were excluded because they 
were healthy controls or because they had a condition other than sarcoidosis.  The remaining 
697 subjects consisted of 155 that were only consented for the biobank and 542 that were 
consented for the biorepository. 
18 
 
Inclusion & Exclusion Criteria 
Subjects with exposure to the heavy metal beryllium were excluded from the 
analyses.  This is due to the similar nature of chronic beryllium disease (CBD) which 
presents in much the same way as sarcoidosis.  If a person has known exposures to beryllium, 
there is a greater chance of misdiagnosis or confounding if the person has both CBD and 
sarcoidosis.  The database contained 25 people with beryllium exposure and 3 of those had a 
diagnosis of CBD.  These subjects were excluded, leaving 672 people. 
In order to be a part of the analysis, each subject needed to have a proven case of 
sarcoidosis.  A ‘proven’ case is considered to be (i.) a person that has had a biopsy with 
granulomas consistent with sarcoidosis and other pathologies are ruled out OR (ii.) a person 
that has presented with the acute form of sarcoidosis known as Lofgren’s syndrome.  Of the 
672 remaining subjects, 582 are considered proven cases and remained for analysis in Aim 1.  
The 90 subjects that were excluded consisted of 41 with unconfirmed sarcoidosis and 49 with 
missing values on biopsy confirmation. 
Aim 2 examined severity of disease using measures that rely greatly on pulmonary 
function.  In fact, one of the severity scores (PSSI) was designed to only assess severity of 
pulmonary involvement.  Therefore, it is important to only include subjects that have lung 
involvement for that severity assessment.  For this reason, only subjects with lung 
involvement were included for Aim 2.  After excluding 21 individuals with no lung 
involvement, 561 subjects remained. 
Finally, in order to perform the severity analyses in Aim 2, certain variables must be 
present for each subject.  It is necessary for the smoking status, PFT values (DLCOpp, 
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FVCpp, FEV1pp), and scadding stage to be known.  Therefore, any records that were missing 
these data points were excluded.  This left 354 for the analyses of Aim 2. 
After taking into consideration the inclusion and exclusion criteria, three 
subpopulations of the original dataset were created.  The first met the bare-minimum 
requirements of being a confirmed sarcoidosis case with no beryllium exposure.  This 
subpopulation (n=582) was used in Aim 1 as a means of describing this unique clinical 
population.  This sample is referred to the “Full sample”.  The second subpopulation/sample 
was derived from the population used in Aim 1.  Therefore, the subjects needed to match the 
same criteria, and each subject also needed to have a confirmed diagnosis and have complete 
data for the Wasfi analysis for spirometry measurements.  Any subject with missing values 
for FVC % predicted (FVCpp) or FEV1/FVC% predicted (FEV1/FVCpp) were excluded.  
This left a sample of 354 people.  This sample is r ferred to as the “Spirometry sample”.  The 
final group used in this analysis also needed to match the criteria for the Aim 1 population.  
However, each subject also needed complete data for the measurements used in the Wasfi 
scoring system for DLCO measurements and the PSSIscoring system.  Since these two 
scoring systems use similar variables, the samples were exactly the same and had a size of 
140 subjects.  This group is now referred to as the “DLCO sample”. 
Data Collection 
Data was collected using three resources: electronic medical records (EMR), 
questionnaires, and physicians’ expertise.  The EMR was used to obtain PFT data, CXR 
scadding stages, smoking status, diagnosis date, organ involvement, age, sex, race/ethnicity, 
and treatment.  The questionnaires were used to supplement the race/ethnicity and smoking 
data.  The questionnaires were either given to the subject in the clinic or mailed to him/her.  
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In total, 262 questionnaires were fil led out and returned for the 582 people used in this study.  
The final resource used in collecting the data is the professional opinions of the physicians in 
the NJH Department of Environmental and Occupational Health.  This resource was used 
only if the information could not be obtained from the two previous sources.  If organ 
involvement could not be definitively obtained through the medical records, a physician 
filled in an organ assessment form.  Furthermore, if scadding stage was not available in the 
EMR, a physician read the CXRs to determine the appropriate scadding stage. 
Study Date 
It is important to note the time point that was chosen as the reference for this study.  
The goal of the study is to assess the association of smoking status and severity of disease at 
a particular point in time.  The time point was chosen on the basis of when there was the 
most complete data.  Therefore, the study date used was the date in which there was PFT, 
spirometry, and CXR data.  If there were multiple dates, the most recent date was chosen.  
This study date was used to calculate age, determine treatment status, and identify the lapsed 
time since diagnosis.  If the subject did not have PFTs, spirometry, or CXR data, the date of 
enrollment into the biorepository was used as the study date to calculate the time-dependent 
variables. 
Variable Definitions 
Tobacco smoking was analyzed as a categorical variable with the options of “never” 
or “ever”.  A subject is considered a never smoker if he/she never smoked tobacco 
(cigarettes, pipe, or cigars), only experimented briefly (less than 1 pack year), or smoked less 
than 1 cigarette per day during the time period in which he/she smoked.  An “ever” smoker is 
a person who is either a former or current smoker.  A former smoker is someone who had at 
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least 1 pack year smoking history and quit smoking before the study date.  A current smoker 
is someone who has a smoke history of at least 1 pack year and currently smoked at the point 
of the study date.     
For the purposes of this analysis, two primary treatment variables were created.  The 
first described all sarcoidosis treatment that a person received up to 30 days prior to the study 
date.  This included corticosteroids, inhaled steroids, and non-steroidal immunosuppressors.  
The variable is dichotomous, indicating therapy as “yes” or “no”. 
The second treatment variable was devised specifically for the Wasfi score.  Wasfi’s 
severity score requires information on non-corticosteroid immunosuppressive therapy.  The 
variable used was dichotomous—yes, the subject was on therapy or no, the subject was not 
on therapy.  A subject was considered to be on therapy if he/she was prescribed any of the 
following drugs (or their name-brand equivalents): Methotrexate (MTX), Adalimumab 
(ADA), Hydroxychloroquine (HCQ), Azathiophrine (AZA), Infliximab (IFX), Leflunamide 
(LEF), Mycophenolate mofitil (MMF), Pentoxifylline (PTX), Chlorambucil (CLB), 
Colchicine (COL), Cyclophosphamide (CTX), Cyclosporine (CSA), or Etanercept (ETA).  
Furthermore, the prescription had to be active within 30 days of the study date.  Otherwise, 
the subject is indicated as not being on therapy.  The important difference between the two 
treatment variables is that the first includes any relevant treatment, whereas the second is 
specially designed to match the needs of aspecific scoring system.  The first treatment 
variable is more appropriate to use to describe the population or as a covariate in statistical 
models. 
Sarcoidosis can affect any organ in the body.  Organ involvement indicates which 
organs are affected.  The ‘usual’ organs that are affected were each represented as a separate 
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dichotomous variable indicating ‘involvement’ or ‘no involvement’.  Specific organ 
involvement was determined by biopsies, lab tests, and/or clinical symptoms.  In most cases, 
this information was obtained through the physician’s notes within the EMR.  However, 
sometimes the notes were not clear or definitive.  In those instances, a list of criteria was 
used to rank the likelihood of involvement.  This was the same method used in a large multi-
center study known as GRADS (Genomic Research in Alpha-1 Antitrypsin Deficiency and 
Sarcoidosis).  If a biopsy of a particular organ showed signs of sarcoidosis, the involvement 
is considered to be highly probable.  Lab tests and clinical symptoms can indicate a range of 
probabilities of involvement from a high probability to little or no probability.  If an organ is 
listed as probable or highly probable, then the subject was assumed to have that particular 
organ involvement.  Otherwise, it was assumed that the organ was not affected by 
sarcoidosis. 
The amount of time that has passed since a person’s diagnosis could affect the 
severity of his/her disease; therefore, it is important to consider this covariate in the analysis.  
However, the available data did not have a specific variable for diagnosis date.  Instead, 
biopsy date was chosen to be a proxy for date of diagnosis.  The time difference (in days) 
between biopsy date and the study date was calculated and resulted in a continuous variable.  
To eliminate any negative values, the “time since diagnosis” variable was considered to be 
zero if the listed biopsy date was after the study date. 
Clinical measurements obtained through pulmonary function tests (PFTs) and chest x-
rays (CXRs) were used in calculating the severity scores.  The PFT measurements used were 
FVC % predicted (FVCpp), FEV1/FVC % predicted (FEV1/FVCpp), and DLCO % 
predicted (DLCOpp).  These are percentages/proportions and were recorded as values 
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between 0 and 1.  The CXR scadding stage is a categorical variable with 5 possible values (0, 
1, 2, 3, and 4).  These values were used in determining the severity scores.  The process of 
calculating the severity scores is explained in the background.   
Other variables used in the analysis include age (measured as discrete years), gender 
(dichotomous), ethnicity (dichotomous indicating Hispanic or non-Hispanic background), 
and race.  Race was originally categorized in five groups: White/Caucasian, Black/African 
American (AA), Asian, Native American, and Other.  A second “race” variable was also 
created specifically for the Wasfi score.  This variable is a dichotomous representation of 
race—black and not black.  Finally, a third variable was created to add as a covariate to the 
analysis for the PSSI score.  This was also a dichotomous variable—white and not white. 
Analysis 
Aim 1 used basic statistical methods to describe the characteristics of the population.  
The frequencies and percentages were calculated for each categorical variable, and the 
average was calculated for each discrete variable.  The full sample (n=582) was characterized 
by several relevant variables.  Then two samples relevant for Aim 2 were also analyzed using 
the same methods.  The first subpopulation (n=354) was used for the analysis of the Wasfi 
score that utilized spirometry measures.  The second subpopulation (n=140) was used to 
analyze the Wasfi score that utilized DLCO measurements and the PSSI score.  These three 
samples were then compared together. 
The correlations between the three severity scores (Wasfi [spirometry], Wasfi 
[DLCO], and PSSI) were analyzed.  Each score was individually compared to each of the 
others.  Pearson’s Correlation Coefficient was used for comparing the two Wasfi scores.  
24 
 
Spearman’s Ranked Correlation Coefficient was used for PSSI compared to each of the 
Wasfi scores. 
Aim 2 used a combination of linear and ordinal logistic regressions to test for 
association between smoking and sarcoidosis severity, using a significance level of 0.05.  
Linear regression was used for the Wasfi score, and ordinal logistic regression was used for 
the ordinal PSSI score.  For the Wasfi scores, the unadjusted measures of association were 
calculated first.  Then adjusted measures were calculated by including relevant covariates in 
the model.  The covariates used in the multivariable analysis were chosen based on  priori 
knowledge and logical consideration.  Age (in years) and gender (categorized as 1= males, 
2= females) could be potential confounders for the relationship between smoking and 
severity.  Time since diagnosis was also placed in the model.  This variable is measured in 
days.  These covariates were considered in each of the analyses.  A log-transformation was 
also performed on the severity scores to determine if a better fit for the data existed.  The log-
transformation did not fit the data better, so it was not included in the Results.  The analysis 
for the PSSI score consisted of three models.  The first was the univariate analysis.  Second 
was the analysis with the three covariates listed above.  The final analysis consisted of the 
previous covariates along with race (categorized as 1=White and 0=Not White), and 
treatment (yes/no within 30 days of the study date).  These covariates were not placed in the 
Wasfi models, because the Wasfi Severity Score already accounted for treatment and race 
(dichotomously).  The models were also analyzed with ethnicity as a covariate.  However, 
the number of missing values for ethnicity dramatically decreased the sample sizes, and the 
primary relationship between smoking and severity was not significantly altered.   
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The PSSI score was analyzed using three ordinal levels.  Even though the score had 
the potential to range from 0 to 7, none of the subjects had the most extreme scores.  The 
observed scores ranged from 2 to 5.  Only two subjects had scores of 5; therefore, the 5-
scores were combined with the 4-scores.  This left three levels—2, 3, and 4—for the analysis. 
A power analysis was performed to determine the sensitivity of the study.  The 
analyses were performed for both the Spirometry group and the DLCO group.  Using the 
maximum standard deviations of the Wasfi scores from this data and the available sample 
sizes, the detectable differences in the means were calculated.  The standard deviation of the 
Wasfi (Spirometry) score for ‘never smokers’ was β.βγ8 and only 2.138 for ‘ever smokers’.  
Therefore, the 2.238 was used as the standard deviation in the sensitivity analysis to be 
conservative.  Similarly, for the Wasfi (DLCO) score, the greater standard deviation was 
found in the group of ‘never smokers’.  It was β.054 and was used for this analysis. 
Finally, a set of analyses was performed on the association between smoking status 
and each of the components of the severity scores.  These analyses were performed on the 
larger Spirometry sample, when possible.  For the DLCO variable, the analysis had to be 
performed on the smaller DLCO sample.  These analyses were performed as explorative 







 Table 2 describes the entire sarcoidosis population of NJH that consented to be a part 
of the biorepository or the biobank—with the exception of those that met the exclusion 
criteria.  The population is predominately white, and there is a fairly even split in gender with 
females making up slightly more of the population.  There is a greater proportion of ‘never’ 
smokers than ‘former’ and ‘current’ combined.  It is also worth noting that there is a greater 
proportion of people that are in scadding stage 2 than any other stage.  Finally, extra-
pulmonary involvement is also listed in Table 1.  Since a single individual can have multiple 
organ involvement, the figures provided in Table 1 will not add up to the total number of 
subjects.  The percentages provided are taken out of the whole sample for each organ.  For 
instance, 13.1% of the population had cardiac involvement; whereas only 7% of the 
population had liver involvement. 
 
Table 2.  Demographics and clinical characteristics of the NJH sarcoidosis clinical 
population. 
Variables Values Percentages 
Age* 51.9 ± 10.7  
Gender   
     Male 280 48.1 
     Female 302 51.9 
Race   
     White 466 80.1 
     Black 95 16.3 
     Asian 4 0.7 
     Native American 2 0.3 
     Other 3 0.5 
     Unknown 12 2.1 
Ethnicity   
     Hispanic 26 4.5 
     Non-Hispanic 410 70.5 
     Unknown 146 25.1 
27 
 
Table 2. Continued 
Variables Values Percentages 
Smoking Status (E/N)   
     Never 385 66.2 
     Ever 194 33.3 




     Never 385 66.2 
     Former 166 28.5 
     Current 28 4.8 
     Unknown 3 0.5 
Smoking Pack Years 
(current and former 
smokers)* 
14.7 ± 15.3  
Time Since Diagnosis 
(Days [Years])* 
1664.0 ± 2379.9 
[4.6 ± 6.5] 
 
Treatment 276 47.4 
Lung Involvement   
     Yes 561 96.4 




     Eyes 60 10.3 
     Skin 71 12.2 
     Cardiac 76 13.1 
     Liver 41 7.0 
     Kidneys 9 1.6 
     Neurological 15 2.6 
     Spleen 21 3.6 
     Hypercalciuria 41 7.0 
     Hypercalcaemia 22 3.8 
Lofgren's Syndrome 17 2.9 
Scadding Stage   
     0 85 14.6 
     1 56 9.6 
     2 174 29.9 
     3 63 10.8 
     4 64 11.0 
     Unknown 140 24.1 
* Average values and standard deviations are provided. 




 Table 3 describes the population in reference to the dichotomized smoking status 
(ever/never).  The group of never smokers is slightly older than the group of former and 
current smokers.  The proportion of males versus females is very similar between the two 
groups.  Race is slightly different with a greater proportion of white subjects and smaller 
proportion of black subjects in the never smoking group than the ever smoking group.  The 
proportions of organ involvement are fairly similar between ever smokers and never 
smokers.  Some of the involved organs do have greater proportions of cases in either the ever 
smoking group or the never smoking group.   Ethnicity, scadding stage, and treatment are all 
quite similar between the groups. 
 
Table 3.  Demographics of the clinical population stratified by smoking status.  The 
percentages are calculated based on the total number of subjects in each category of smoking 
status. 
Demographics  Smoking Status  
 Ever  
n (column %) 
Never  
n (column %) 
Unknown 
Age* 48.9 ± 12.0 53.5 ± 9.7  
Gender    
     Male 94 (48.5) 186 (48.3) 0 (0) 
     Female 100 (51.6) 199 (51.2) 3 (100) 
Race    
     White 144 (74.2) 320 (83.1) 2 (66.7) 
     Black 45 (23.2) 49 (12.7) 1 (33.3) 
     Asian 0 (0) 4 (1.0) 0 (0) 
     Native American 1 (0.5) 1 (0.3) 0 (0) 
     Other 0 (0) 3 (0.8) 0 (0) 
     Unknown 4 (2.1) 8 (2.1) 0 (0) 
Ethnicity    
     Hispanic 13 (6.7) 13 (3.4) 0 (0) 
     Non-Hispanic 127 (65.5) 282 (73.3) 1 (33.3) 




2031.7 ± 2993.5 
[5.4 ± 8.2] 
1491.7 ± 1986.4 
[4.1 ± 5.4] 
 
Treatment 86 (44.3) 190 (52.2)  
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Table 3. Continued 
Demographics  Smoking Status  
 Ever 
n (column %) 
Never 
n (column %) 
Unknown 
Lung Involvement 185 (95.4) 373 (49.4) 3 (100) 
Extra-pulmonary 
Involvement ⱡ 
   
     Eyes 28 (14.4) 31 (8.1) 1 (33.3) 
     Skin 32 (16.5) 39 (10.1)  
     Cardiac 22 (11.3) 54 (14.0)  
     Liver 13 (6.7) 28 (7.3)  
     Kidneys 4 (2.1) 5 (1.3)  
     Neurological 7 (3.6) 7 (1.8) 1 (33.3) 
     Spleen 6 (3.1) 15 (3.9)  
     Hypercalciuria 14 (7.2) 27 (7.0)  
     Hypercalcaemia 5 (2.6) 17 (4.4)  
Lofgren's Syndrome 5 (2.6) 12 (3.1)  
Scadding Stage    
     0 26 (13.4) 59 (15.3)  
     1 17 (8.8) 39 (10.1)  
     2 60 (30.9) 114 (29.6)  
     3 19 (9.8) 44 (11.4)  
     4 25 (12.9) 39 (10.1)  
     Unknown 47 (24.2) 90 (23.4) 3 (100) 
* Average values and standard deviations are provided. 




 Table 4 compares the three samples used in this study.  The pertinent variables were 
compared across the three samples.  Some variables, such as DLCOpp and Wasfi severity 
score, could only be included for the samples that had the complete information for those 
variables.  The purpose of Table 4 is to identify any major differences in the demographic 
and clinical manifestations of sarcoidosis between the study samples.  Although there are 
minor differences among the groups, the three samples are very similar with regards to all of 
these factors.  There do not appear to be any consequential differences for interpretation of 
the severity analyses in Aim 2. 
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Table 4.  The demographics and clinical data are shown for all 3 study samples. 
Variables Full Sample Spirometry Sample DLCO Sample 
Age* 51.9 ± 10.7 52.1 ± 10.6 54.1 ± 9.9 
Gender    
     Male 280 (48.1) 187 (52.8) 70 (50.0) 
     Female 302 (51.9) 167 (47.2) 70 (50.0) 
Race    
     White 466 (80.1) 286 (80.8) 108 (77.1) 
     Black 95 (16.3) 58 (16.4) 29 (20.7) 
     Asian 4 (0.7) 1 (0.3) 1 (0.7) 
     Native American 2 (0.3) 1 (0.3) 1 (0.7) 
     Other 3 (0.5) 3 (0.9) 0 (0.0) 
     Unknown 12 (2.1) 5 (1.4) 1 (0.7) 
Ethnicity    
     Hispanic 26 (4.5) 19 (5.4) 3 (2.1) 
     Non-Hispanic 410 (70.5) 274 (77.4) 113 (80.7) 
     Unknown 146 (25.1) 61 (17.2) 24 (17.1) 
Smoking Status    
     Never 385 (66.2) 242 (68.4) 102 (72.9) 
     Ever 194 (33.3) 112 (31.6) 38 (27.1) 
     Unknown 3 (0.5)   
Smoking Pack Years 
(current and former 
smokers)* 




1664.0 ± 2379.9 
[4.6 ± 6.5] 
1964.6 ± 2282.8 
[5.4 ± 6.3] 
2364.6 ± 2601.4 
[6.5 ± 7.1] 
Treatment 276 (47.4) 201 (56.8) 98 (70.0) 
Lung Involvement 561 (95.4) 354 (100.0) 140 (100.0) 
Extra-pulmonary 
Involvement ⱡ 
   
     Eyes 60 (10.3) 30 (8.5) 10 (7.1) 
     Skin 71 (12.2) 40 (11.3) 16 (11.4) 
     Cardiac 76 (13.1) 52 (14.7) 30 (21.4) 
     Liver 41 (7.0) 26 (7.3) 15 (10.7) 
     Kidneys 9 (1.6) 6 (1.7) 3 (2.1) 
     Neurological 15 (2.6) 10 (2.8) 1 (0.7) 
     Spleen 21 (3.6) 13 (3.7) 8 (5.7) 
     Hypercalciuria 41 (7.0) 33 (9.3) 18 (12.9) 
     Hypercalcaemia 22 (3.8) 16 (4.5) 9 (6.4) 




Table 4. Continued 
Variables Full Sample Spirometry Sample DLCO Sample 
Scadding Stage    
     0 85 (14.6) 66 (18.6) 21 (15.0) 
     1 56 (9.6) 41 (11.6) 13 (9.3) 
     2 174 (29.9) 146 (41.2) 56 (40.0) 
     3 63 (10.8) 50 (14.1) 23 (16.4) 
     4 64 (11.0) 51 (14.4) 27 (19.3) 
     Unknown 140 (24.1)   
    
DLCO % predicted   76.5 ± 16.3 
FVC % predicted  88.1 ± 16.1 86.0 ± 15.4 
 FEV1/FVC ratio  94.2 ± 11.7 92.7 ± 11.9 
    
Wasfi Severity 
Score (Spiro)* 
 3.105 ± 2.205 3.724 ± 2.159 
Wasfi Severity 
Score (DLCO)* 
  3.871 ± 2.003 
Hamzeh Severity 
Score 
   
     0   0 (0) 
     1   0 (0) 
     2   32 (22.9) 
     3   76 (54.3) 
     4   30 (21.4) 
     5   2 (0.1) 
     6   0 (0) 
     7   0 (0) 
* Average values and standard deviations are provided. 
ⱡ  Percentages are calculated for each type of organ involvement, individually. 
 
 Table 5 lists the three severity scores and their correlations to each other.  To 
determine the correlations, the smallest sample with the most complete date—DLCO 
sample—was used.  As expected, the two Wasfi scores are highly correlated with each other.  
However, both Wasfi scores are very mildly positively correlated with the PSSI score.  Even 

























Table 6.  Results of the univariate and multivariable analysis of the Wasfi score (using 
spirometry measurements) as it is related to smoking status. 
Wasfi Score 
(spirometry) 
   
Predictor 
Variables 





   
Smoking Status 0.171 -0.γβ5 0.667 0.4987 
    
Multivariable 
Analysis 
   
Smoking Status 0.179 -0.γγ0 0.688 0.4899 
Age 0.015 -0.008 0.0γ8 0.2416 
Gender -0.500 -0.966 -0.0γ4 0.0354 
Time Since 
Diagnosis 
0.0001 0.01γ 0.089 0.0094 
 
 Table 6 describes the relationship between cigarette smoking status and the Wasfi 
scoring system for spirometry measures.  A multiple linear regression was calculated to 
predict the severity score based on the primary explanatory variable (PEV) of smoking status 
(coded as Ever =1 and Never =0) and the covariates gender (coded as Male =1 and Female 
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=2), age (in years), and the amount of time since diagnosis (in days).  Gender and time since 
diagnosis were the only statistically significant predictors (p≤0.05) of the severity of disease 
in this model. There is no statistical difference between the ‘ever smokers’ and ‘never 
smokers’.  This is true for the simple analysis, in which the effect size of smoking was 0.171 
with a 95% confidence interval (CI) of -0.325 to 0.667 and a p-value of 0.4987, indicating no 
statistical significance.  This is also true for the multivariable analysis (effect=0.179; 95%CI: 
-0.330, 0.688; p=0.4899).    
 Likewise, Table 7 shows the qualitative interpretation of the results did not change for 
the analysis with the DLCO sample (n=140) using the Wasfi score for DLCO measures.  In 
the simple analysis, smoking was not significantly associated with severity (effect=0.484; 
95%CI: -0.267, 1.235; p=0.2047), nor was it associated after adjusting for the covariates 
(effect=0.414; 95%CI: -0.372, 1.200; p=0.2992). 
 
Table 7.  Results of the univariate and multivariable analysis of the Wasfi score (using 
DLCO values) as it is related to smoking status. 
Wasfi Score 
(DLCO) 
   
Predictor 
Variables 





   
Smoking Status 0.484 -0.β67 1.βγ5 0.2047 
    
Multivariable 
Analysis 
   
Smoking Status 0.414 -0.γ7β 1.β00 0.2992 
Age -0.006 -0.041 0.0γ0 0.7595 
Gender -0.161 -0.867 0.546 0.6534 
Time Since 
Diagnosis 




 Finally, Table 8 shows the results of the analysis of the PSSI scoring system.  Since 
this system requires DLCO measures, the DLCO sample (n=140) was used for this analysis.  
It was again found that there is no significant difference in severity between ‘never smokers’ 
and ‘ever smokers’ (Odds Ratio [OR]=1.670; 95%CI: 0.812, 3.432; p=0.1631).  This is true 
for the first multivariable model (OR=1.807, 95%CI: 0.827, 3.946; p=0.1378) that adjusted 
simply for gender, age, and time since diagnosis.  The results were similar for the second 
multivariable model (OR=1.912, 95%CI: 0.829, 4.410; p=0.1290) that also adjusted for 
treatment and race. 
 
Table 8.  Results of the univariate and multivariable analysis of the PSSI score as it is related 
to smoking status. 
PSSI Score    
Predictor 
Variables 
Odds Ratio 95% Confidence 
Interval 
p-value 
Univariate Analysis    
Smoking Status 1.670 0.812 3.432 0.1631 
    
Multivariable 
Analysis 1 
   
Smoking Status 1.807 0.827 3.946 0.1378 
Age 0.994 0.960 1.030 0.7333 
Gender 0.691 0.344 1.387 0.2981 
Time Since 
Diagnosis 
1.000 1.000 1.000 0.0042 
    
Multivariable 
Analysis 2 
   
Smoking Status 1.912 0.829 4.410 0.1290 
Age 0.993 0.956 1.032 0.6851 
Gender 0.664 0.317 1.394 0.2818 
Treatment 1.178 0.491 2.825 0.7196 
Time Since 
Diagnosis 
1.000 1.000 1.000 0.0248 




 A power analysis was performed to identify the minimum differences in the means 
that could be detected in this study.  The results are shown in Table 9 and were obtained 
using a standard deviation of 2.24 for the Wasfi (spirometry) score and 2.05 for the Wasfi 
(DLCO) score.  Given particular sample sizes and 80% power, the study would have been 
able to detect differences in the means of as little as 0.73 for the Wasfi (spirometry) analysis 
and 1.12 for the Wasfi (DLCO) analysis.   
 
Table 9. A sensitivity analysis was performed to determine detectable differences in the 
means. 
Power Detectable Mean Difference* 
 Wasfi Score (Spirometry) Wasfi Score (DLCO) 
0.80 0.72 1.10 
0.90 0.83 1.27 
0.95 0.92 1.42 







 The whole NJH sarcoidosis population has never been used for research in the past. 
Limited subgroups within the population have been used for some studies.  However, the 
population as a whole has not been described before now.  The sample used in this study is 
likely to be an acceptable representation of this entire sarcoidosis population seen at NJH.  
Facilitated by the ease of enrollment and participation in the biorepository and biobank, a 
substantial portion of the sarcoidosis patients agreed to be a part of those registries.  Since 
this study draws its sample from those sources, it can be assumed that the study sample is 
adequately representative of the clinical population at NJH.  It is important to note that NJH 
is a specialized referral center.  Therefore, the sample used for this study is a good 
representation of aspecialty clinic population and not a general practice sarcoidosis 
population.  Most of NJH’s patients have been diagnosed with sarcoidosis previously and 
then referred to NJH.  Thus, certain types of sarcoid cases are more likely to be found at NJH 
than other types.  For instance, people with more severe sarcoidosis and/or more 
complications associated with their disease may be more likely to go to NJH.  Also, people 
that have the means of traveling to and being seen at NJH may be different compared to the 
general population of sarcoid cases.  This population would be geographically influenced, 
too.  Sarcoid cases from Colorado or the U.S. Western or Midwestern states would have 
greater ease of access to NJH than people from other parts of the country.  When describing 
this sample, it is crucial to understand that this is meant to describe a clinical population, 
specifically one from a specialized referral hospital. 
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 The sample has a fairly even distribution of males and females; race and ethnicity are 
less homogenous.  The majority of sarcoidosis cases at the clinic are white, consisting of 
almost five times as many people as any other race.  African Americans are the second most 
prominent group.  Although the incidence of sarcoidosis is greater in black peoples, the 
demographic makeup of the country means that, in sheer numbers, more white people will 
have sarcoidosis.  This may also be influenced by the fact that this is a specialized clinic.  
The NJH population is also not very ethnically diverse.  The vast majority of subjects with 
‘known’ ethnicity is non-Hispanic.  This is again likely due to the same factors that influence 
the racial composition of the group.  It is also worth noting that there was a lot of missing 
data for ethnicity, since it is often not recorded in the medical records.  That is the primary 
reason for excluding ethnicity from the regression analyses in Aim 2.   
 The purpose of Table 3 is to identify any significant differences in the smoking versus 
non-smoking groups, based on the variables of interest.  Some statistically significant 
differences—based on a five percent significance level—did exist, such as age, race, and the 
amount of time that elapsed since diagnosis.  Given this information, it was important to 
adjust the models in Aim 2 for these variables.  There were some other slight differences, but 
any of them could easily be attributed to chance.  Overall, the two categories of smoking 
status are similar in demographic and clinical characteristics. 
 Table 4 compares and contrasts across the three study samples.  The samples are very 
consistent across all of the variables.  Even though missing data prevented the use of the full 
sample for the analyses in Aim 2, the results for the smaller samples would likely be suitable 




How closely the severity scores correlate with each other is shown in Table 5.  The 
two Wasfi scores (Spirometry and DLCO) are highly correlated (r=0.96, p<0.0001).  This is 
expected considering these two scores are calculated from almost the same set of variables.  
However, the Wasfi scores are not nearly as correlated with the PSSI score.  There is a small 
positive correlation (r=0.171) between the Wasfi (spirometry) score and the PSSI score, and 
it is borderline significant (p=0.043).  Likewise, the Wasfi (DLCO) score and the PSSI score 
are mildly positively correlated (r=0.242), but this correlation is much for significant 
(p=0.004).  Therefore, it is unlikely that this slight correlated relationship is due to chance.  
This analysis demonstrates that even though each of the scores is calculated using different 
methods, each is ultimately measuring disease severity in the ‘same direction’.  In other 
words, as one indicates increased severity, the others will do the same.  However, there is 
still very minimal correlation between the Wasfi scores and the PSSI.  This is most likely due 
to differences in the scale of the scores.  The correlations were determined using the 
Spearman Rank methods, which is appropriate for ordinal data.  However, comparing a 
continuous variable with an ordinal variable is limiting.  Furthermore, the scores were 
developed to accomplish different goals.  The purpose of the Wasfi score was to include 
various characteristics, including extra-pulmonary involvement, to determine severity of 
disease.  On the other hand, the PSSI was developed to characterize only pulmonary disease. 
 According to the results obtained from the analyses of Aim 2, there is not enough 
evidence to suggest that smoking status impacts the severity of sarcoidosis as measured by 
the Wasfi and PSSI scoring systems.  Table 9 shows the results of the power analysis.  The 
Wasfi (spirometry) analysis could detect a mean difference of 0.72 with 80% power and a 
significance level of 0.05.  The Wasfi (DLCO)—which utilized a much smaller sample—
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could detect a mean difference as little as 1.10 with 80% power and a significance level of 
0.05.  This study cannot rule out the possibility of a smaller effect of smoking on severity 
than the upper limits on the confidence intervals for each difference.    In fact, even though 
none of the associations were significant, the effect sizes of smoking status were all in the 
direction that is expected from one of the study’s hypotheses.  Although smoking status is 
negatively associated with development of disease, it is suspected that once a person has 
sarcoidosis, the disease may be more severe in current and former smokers.   Cigarette 
smoking causes long-term damage to the body, specifically the airways and lungs.  The 
hypothesis is that cigarette smoking may help to suppress the immune system to prevent 
development of disease—at least for a time.  However, once a person has the disease, the 
damage caused by cigarette smoking may accentuate the damage caused by the sarcoidosis 
disease process.  This study cannot conclude that there is an association between smoking 
and severity, but it also cannot rule out the possibility. 
 Another potential explanation for failing to see an association may be due to a 
“washout effect”.  This study hypothesized that smoking may be either positively or 
negatively associated with severity of disease.  Perhaps in some people—due to a number of 
factors—there is a positive association between smoking and severity, but in others there is a 
negative association.  This could result in a negligible observed association.   
To further analyze this association, larger sample sizes with more complete data 
would be beneficial.  The analysis would further benefit by using only data obtained at the 
time of diagnosis.  This could decrease potential confounders, avoid issues of recall, and 
investigate a more direct question—severity at the time of diagnosis.  These factors could aid 
in detecting an association of smaller effect or providing more definitive proof that there is 
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no effect of smoking on severity.  Another useful analysis would include examining the 
effect of smoking status, categorized as ‘current’, ‘former’, and ‘never’.  It could be that 
current smoking status is the most important factor in determining an association with 
severity.  In fact, if there is a negative association between smoking and disease severity, it is 
biologically reasonable that current smoking would have a greater impact than ever smoking.  
Another useful set of analyses would be to examine the effect of the quantity of cigarette 
smoking, such as pack years or cigarettes per day.   These analyses may uncover a specific 
association that could result in a more complete understanding of the biological mechanisms 
of sarcoidosis in the context of tobacco exposure.  
Other factors may have influenced the outcomes of this study.  There are several 
potentially relevant variables that were not taken into account due to limitations in the 
dataset.  For instance, socioeconomic status (SES) could have possibly confounded the 
relationship between smoking status and severity of disease, but our data had no way of 
indicating SES.  Another variable that would have strengthened the validity of the results 
would have been an actual date of diagnosis.  As stated previously, biopsy date was used as a 
substitute for that variable.  Many of the biopsies performed and recorded were the original 
biopsies used to diagnose a patient.  However, this is not always the case.  If a subject was 
diagnosed by a biopsy long before coming to NJH and NJH has no direct evidence of the 
results of that procedure, a more recent biopsy (if one was performed) would be recorded.  
Furthermore, some patients are given a clinical diagnosis of sarcoidosis and do not receive a 
biopsy for several years.  In both of these cases, the subjects may have worsening disease 
progression and/or have been prescribed treatment before the recorded biopsy date.  
Therefore, diagnosis date would be more appropriate to use than biopsy date in determining 
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the ‘time since diagnosis’.  However, with the data available, using biopsy date should be a 
reasonable proxy.  The potential problems associated with our proxy measure are likely 
mitigated by the fact that the majority of individuals have a biopsy very close to the diagnosis 
date. 
As alluded to previously, a valuable study for analyzing the scoring systems—
primarily the PSSI—would be to use a population consisting of clinical measures taken at 
baseline and longitudinally.  Ideally, each subject would have the CXR scadding stage and 
PFT measurements collected shortly after diagnosis and before being prescribed therapy.  
This would eliminate the possibility that therapy may play a role as a confounding, 
modifying, or interaction variable.  However, limiting the analysis to people with baseline 
measures would have decreased the power significantly.  Furthermore, this population was 
obtained from NJH, which is a referral medical facility.  Most of the patients have been seen 
and treated by other doctors at other facilities.  Therefore, a substantial portion of patients 
would not have their baseline measurements through NJH, and sometimes it is not always 
clear if the measurements were taken at baseline or when a person was prescribed 
medication.  Therefore, the best way to try to eliminate confounding issues with medication 
use was to include treatment in the model.  As mentioned previously, this had no effect. 
 Another limitation to this study was due to an alteration in the Wasfi protocol.  In 
Wasfi’s study, immunosuppressive therapy was described as taking one of any number of 
drugs—some of which are no longer widely used.  Some of those therapies have been 
replaced by other medications.  So, for the purposes of this study, all the medications listed 
under the Methods section were considered as immunosuppressive therapy.  Likely this 
would not affect the overall validity of the study.  Two physicians with expertise in 
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sarcoidosis were consulted, and they felt that using different drugs would not affect the 
results.  The drugs have the same purpose and are still mainly prescribed to the same types of 
people as the outdated drugs. 
 Arguably the greatest limitation of this study and most sarcoidosis studies is the lack 
of longitudinal data.  This study consists of cross-sectional data, because that is what was 
available.  There is a dire need for longitudinal data on sarcoidosis.  This matter has been 
repeatedly stressed by medical and research professionals and research institutions and 
organizations, including the NIH.  Setting up a system to follow sarcoidosis cases long-term 
has been challenging in many ways.  The most encompassing challenge is the basic deficit of 
knowledge of sarcoidosis.  This includes understanding sarcoidosis populations.  The NIH 
continues to underscore the need for more data on sarcoid populations.  Closely examining 
clinical sarcoidosis populations—even at a cross-sectional level—should provide valuable 
information on the epidemiology of sarcoidosis.  This information could be used to better 
design future studies and set up the infrastructure needed to track patients over time.   
 The exact relationship between tobacco smoking and sarcoidosis cannot be 
ascertained without longitudinal data.   Knowing that cigarette smoking is associated with a 
decreased risk of the development of sarcoidosis, clinicians have long wondered if it is also 
associated with severity of disease.  Determining the answer to that question may lead to a 
better understanding of the physiological mechanisms behind the development and 
progression of the disease.  This study used available data as a starting point to explore that 
question.  It is the hope of this study that describing the clinical population and performing 
cross-sectional analyses will provide a greater base knowledge of sarcoidosis that will 
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Associations of Smoking Status and Individual Component Variables of Each Severity 
Score 
 





95% Confidence Interval p-value 
Univariate 
Analysis 
     
Smoking 
Status 
-1.878 1.864 -5.543 1.787 0.3142 
      
Multivariable 
Analysis 
     
Smoking 
Status 
-2.887 1.945 -6.713 0.939 0.1386 
Age -0.305 0.088 -0.478 -0.132 0.0006 
Gender 2.682 1.779 -0.818 6.181 0.1326 
Time Since 
Diagnosis 
-0.0004 0.0004 -0.001 0.0004 0.3049 
 





95% Confidence Interval p-value 
Univariate 
Analysis 
     
Smoking 
Status 
-3.866 1.331 -6.483 -1.248 0.0039 
      
Multivariable 
Analysis 
     
Smoking 
Status 
-2.829 1.393 -5.568 -0.089 0.0431 
Age 0.087 0.063 -0.037 0.210 0.1699 
Gender 3.422 1.274 0.915 5.928 0.0076 
Time Since 
Diagnosis 









95% Confidence Interval p-value 
Univariate 
Analysis 
     
Smoking 
Status 
-8.711 3.066 -14.773 -2.649 0.0052 
      
Multivariable 
Analysis 
     
Smoking 
Status 
-7.265 3.142 -13.484 -1.046 0.0224 
Age -0.107 0.143 -0.391 0.176 0.4546 
Gender 2.936 2.822 -2.650 8.522 0.3002 
Time Since 
Diagnosis 














      
Smoking 
Status 
0.159 0.207 1.172 0.781 1.759 0.4424 
       
Multivariable 
Analysis 
      
Smoking 
Status 
0.233 0.222 1.262 0.817 1.949 0.2938 
Age 0.022 0.010 1.022 1.002 1.042 0.0312 
Gender -0.529 0.204 0.589 0.395 0.880 0.031 
Time Since 
Diagnosis 
















      
Smoking 
Status 
-0.195 0.239 0.823 0.515 1.315 0.4149 
       
Multivariable 
Analysis 
      
Smoking 
Status 
-0.163 0.255 0.850 0.516 1.400 0.5229 
Age 0.012 0.012 1.012 0.989 1.035 0.3121 
Gender -0.121 0.231 0.886 0.563 1.395 0.6023 
Time Since 
Diagnosis 














      
Smoking 
Status 
-0.265 0.336 0.767 0.397 1.482 0.4296 
       
Multivariable 
Analysis 
      
Smoking 
Status 
-0.212 0.365 0.809 0.396 1.655 0.5618 
Age 0.006 0.016 1.006 0.975 1.039 0.7011 
Gender -0.383 0.330 0.682 0.357 1.302 0.2455 
Time Since 
Diagnosis 
















      
Smoking 
Status 
0.795 0.643 2.215 0.628 7.812 0.2162 
       
Multivariable 
Analysis 
      
Smoking 
Status 
0.433 0.753 1.542 0.352 6.751 0.5633 
Age -0.059 0.038 0.943 0.875 1.016 0.1240 
Gender 0.648 0.763 1.912 0.429 8.532 0.3955 
Time Since 
Diagnosis 














      
Smoking 
Status 
0.766 0.340 2.150 1.104 4.186 0.0243 
       
Multivariable 
Analysis 
      
Smoking 
Status 
0.653 0.362 1.921 0.944 3.909 0.0716 
Age -0.024 0.017 0.976 0.943 1.010 0.1616 
Gender 0.166 0.355 1.180 0.588 2.366 0.6410 
Time Since 
Diagnosis 








/*Complete code for reading in data and assigning variables. 




LIBNAME Data '/home/sarah.schrock/Thesis/Data'; 
LIBNAME final '/home/sarah.schrock/Thesis/Data/Final'; 
LIBNAME check '/home/sarah.schrock/Thesis/Data/check'; 
 
 














IF PrimaryDx NE 'Sarc' THEN DELETE; 
*Delete CBD subjects; 
IF SecondaryDx EQ 'CBD' THEN DELETE; 
*Calculate current age; 
CurrentAge = INT(YRDIF(DOB, TODAY(), 'Actual')); 
*Set up AA race yes/no; 
IF Race = 2 THEN AArace = 1; 
IF Race = '.' THEN AArace = '.'; 
ELSE AArace = 0; 
*Set up variable for ever/never smoke; 
IF Smoke = 'never' THEN ENSmoke = 0; 
IF Smoke = 'previous' or smoke = 'current' THEN ENSmoke = 1; 
IF Smoke = ' ' THEN ENSmoke = '.'; 
*Calculate cigs/day based on average; 
IF ENSmoke = 1 THEN DO; 
 Cigs = (20*PackYr) / (SmokeStop - SmokeStart); 
 END; 
*Remove BeExposed; 
IF BeExposed = 1 THEN DELETE; 
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*keep only confirmed cases; 
IF LofgrensSyndrome EQ 0 THEN DO; 





/*Read in the PFT dataset*/ 
DATA data.PFTset; 
SET data.pft; 
IF DLCO NE ' ' OR DLCOpp NE ' ' THEN DLCOdata = 1; 




/*Merge the datasets (main and pft)*/ 
PROC SORT DATA=data.fullset; 
BY sarsID; 
RUN; 










*Create a dataset that will determine matching PFT and CXR dates; 
DATA data.wholesetb; 
SET data.wholeset; 
*Create variables for the difference between PFT and CXR dates; 
IF CxrInitialDate NE '.' AND Obs_Date NE '.' THEN DO; 
 Date_IcxrPft = ABS(DATDIF (CxrInitialDate, Obs_Date, 'act/act')); 
 END; 
 ELSE Date_IcxrPft = 99999; 
IF Cxr2yrDate NE '.' AND Obs_Date NE '.' THEN DO; 
 Date_2cxrPft = ABS(DATDIF (Cxr2yrDate, Obs_Date, 'act/act')); 
 END; 
 ELSE Date_2cxrPft = 99999; 
IF Cxr4yrDate NE '.' AND Obs_Date NE '.' THEN DO; 
 Date_4cxrPft = ABS(DATDIF (Cxr4yrDate, Obs_Date, 'act/act')); 
 END; 






/*Handle dates, dlco, and multiple scadding*/ 
*Create dataset for the PFTs that match best with the initial CXR date; 
*Sort by ID to keep records together, by descending DLCOdata to make sure DLCO orders 
are first, then by date difference between Initial CXR and PFT order date; 
PROC SORT DATA=data.wholesetb; 





BY sarsID DESCENDING DLCOdata Date_IcxrPft; 
IF FIRST.sarsID; 
*Create variable that can be compared across records; 
InterestDate = Date_IcxrPft; 
*Create variable to indicate that this record was chosen in reference to the initial date; 




*Create dataset for the PFTs that match best with the 2nd year CXR date; 
PROC SORT DATA=data.wholesetb; 





BY sarsID DESCENDING DLCOdata Date_2cxrPft; 
IF FIRST.sarsID; 
InterestDate = Date_2cxrPft; 
Yr2 = 1; 
RUN; 
 
*Create dataset for the PFTs that match best with the 4th year CXR date; 
PROC SORT DATA=data.wholesetb; 





BY sarsID DESCENDING DLCOdata Date_4cxrPft; 
IF FIRST.sarsID; 






*Combine datasets and delete any records with missing dates (aka missing scadding stage); 
DATA data.combined; 
SET data.YrInitial data.Yr2 data.Yr4; 
IF InterestDate = 99999 THEN DELETE; 
RUN; 
 





/*Finish choosing the correct pft record*/ 
*Create a dataset that chooses only the records with the pft dates closest to the CXR date; 
PROC SQL; 
create table data.chosen as 
select * 
from data.combined as a 
group by a.sarsID 
having a.InterestDate = MIN(InterestDate); 
QUIT; 
 
*Create a dataset where the date-indicator variables are combined into 1; 
DATA data.chosen2; 
SET data.chosen; 
IF YrInit = 1 THEN UseDate = 1; 
ELSE IF Yr2 = 1 THEN UseDate = 2; 
ELSE IF Yr4 = 1 THEN UseDate = 3; 
RUN; 
 
PROC SORT DATA=data.chosen2; 




*Choose the final record that will be used by picking the most recent date; 
DATA data.chosen3; 
SET data.chosen2; 
BY sarsID DESCENDING DLCOdata DESCENDING UseDate; 
IF FIRST.sarsID; 
IF UseDate = 1 THEN ScadStage = CxrInitialScadStage; 
ELSE IF UseDate = 2 THEN ScadStage = Cxr2yrScadStage; 
ELSE IF UseDate = 3 THEN ScadStage = Cxr4yrScadStage; 
IF UseDate = 1 THEN StudyDate = CxrInitialDate; 
ELSE IF UseDate = 2 THEN StudyDate = Cxr2yrDate; 
ELSE IF UseDate = 3 THEN StudyDate = Cxr4yrDate; 
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/*Calculate severity scores*/ 
DATA final.drugs; 
SET final.complete; 
*Calculate age based on clinical date; 
IF StudyDate NE '.' THEN DO; 
 Age = INT(YRDIF(DOB, StudyDate, 'Actual')); 
 END; 
ELSE Age = '.'; 
*Create variable to indicate recent medication use...using the fact that I filled the blank slots 
in order.  If there is not 2nd drug, there is no 3rd drug; 
IF StudyDate NE '.' THEN DO; 
 IF d2ndDrug = ' ' THEN RecTreat2 = '0'; 
 IF d2ndDrug NE ' ' THEN DO; 
 IF d2ndDrugStarted NE '.' THEN DO; 
 *If study date is before the start of the drug, then no treatment; 
 IF d2ndDrugStarted GE StudyDate THEN RecTreat2 = '0'; 
 *If study date is between start and stop dates, then there is treatment; 
 IF d2ndDrugStarted LT StudyDate AND d2ndDrugStopped = '.' THEN RecTreat2 = 
'1'; 
 IF d2ndDrugStarted LT StudyDate AND d2ndDrugStopped GE StudyDate THEN 
RecTreat2 = '1'; 
 *If study date is after stop date, then it is time dependent; 
 IF d2ndDrugStopped NE '.' AND d2ndDrugStopped LT StudyDate THEN DO; 
  TreatDiff2 = INT(DATDIF(d2ndDrugStopped, StudyDate, 'ACT/ACT')); 
  IF TreatDiff2 NE '.' AND TreatDiff2 LE 30 THEN RecTreat2 = '1'; 
  ELSE IF TreatDiff2 NE '.' THEN RecTreat2 = '0'; 




ELSE RecTreat2 = ' '; 
*Create variable to indicate recent medication use...using the fact that I filled the blank slots 
in order.  If there is not 2nd drug, there is no 3rd drug; 
IF StudyDate NE '.' THEN DO; 
 IF d3rdDrug = ' ' THEN RecTreat3 = '0'; 
 IF d3rdDrug NE ' ' THEN DO; 
 IF d3rdDrugStarted NE '.' THEN DO; 
 *If study date is before the start of the drug, then no treatment; 
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 IF d3rdDrugStarted GE StudyDate THEN RecTreat3 = '0'; 
 *If study date is between start and stop dates, then there is treatment; 
 IF d3rdDrugStarted LT StudyDate AND d3rdDrugStopped = '.' THEN RecTreat3 = 
'1'; 
 IF d3rdDrugStarted LT StudyDate AND d3rdDrugStopped GE StudyDate THEN 
RecTreat3 = '1'; 
 *If study date is after stop date, then it is time dependent; 
 IF d3rdDrugStopped NE '.' AND d3rdDrugStopped LT StudyDate THEN DO; 
  TreatDiff3 = INT(DATDIF(d3rdDrugStopped, StudyDate, 'ACT/ACT')); 
  IF TreatDiff3 NE '.' AND TreatDiff3 LE 30 THEN RecTreat3 = '1'; 
  ELSE IF TreatDiff3 NE '.' THEN RecTreat3 = '0'; 




ELSE RecTreat3 = ' '; 
 *Determine non-corticoidsteroid medication use; 
 IF RecTreat2 = ' ' AND RecTreat3 = ' ' THEN treatment = '.'; 
 ELSE IF RecTreat2 = '1' OR RecTreat3 = '1' THEN treatment = 1; 
 ELSE IF RecTreat2 = '0' AND RecTreat3 = ' ' THEN treatment = 0;  





*Create variable to indicate recent prednisone use...using the fact that I filled the blank slots 
in order.  If there is not 2nd drug, there is no 3rd drug; 
IF StudyDate NE '.' THEN DO; 
 IF Prednisone = ' ' THEN RecPred = ' '; 
 IF Prednisone = 'no' THEN RecPred = '0'; 
 IF Prednisone EQ 'yes' THEN DO; 
 IF PredStarted NE '.' THEN DO; 
 *If study date is before the start of the drug, then no treatment; 
 IF PredStarted GE StudyDate THEN RecPred = '0'; 
 *If study date is between start and stop dates, then there is treatment; 
 IF PredStarted LT StudyDate AND PredStopped = '.' THEN RecPred = '1'; 
 IF PredStarted LT StudyDate AND PredStopped GE StudyDate THEN RecPred = '1'; 
 *If study date is after stop date, then it is time dependent; 
 IF PredStopped NE '.' AND PredStopped LT StudyDate THEN DO; 
  PredDiff = INT(DATDIF(PredStopped, StudyDate, 'ACT/ACT')); 
  IF PredDiff NE '.' AND PredDiff LE 30 THEN RecPred = '1'; 
  ELSE IF PredDiff NE '.' THEN RecPred = '0'; 






ELSE RecPred = ' '; 
 *Create numeric variable for pred used; 
 IF RecPred = ' ' THEN PredTreat = '.'; 
 IF RecPred = '0' THEN PredTreat = 0; 
 IF RecPred = '1' THEN PredTreat = 1; 
 *Create variable for pred and immmunosupp use; 
 IF treatment = '.' AND PredTreat = '.' THEN PredImm = '.'; 
 ELSE IF treatment = 1 OR PredTreat = 1 THEN PredImm = 1; 
 ELSE IF treatment = 0 AND PredTreat = '.' THEN PredImm = '.';  
 ELSE IF treatment = '.' AND PredTreat = 0 THEN PredImm = 0;  
 ELSE IF treatment = 0 AND PredTreat = 0 THEN PredImm = 0; 
 *Create variable for pred and inhaled used; 
 IF PredTreat = '.' AND InhaledSteroid = ' ' THEN PredInh = '.'; 
 IF PredTreat = 0 AND InhaledSteroid = ' ' THEN PredInh = 0; 
 IF PredTreat = 0 AND InhaledSteroid NE ' ' THEN PredInh = 1; 
 IF PredTreat = 1 AND InhaledSteroid = ' ' THEN PredInh = 1; 
 IF PredTreat = 1 AND InhaledSteroid NE ' ' THEN PredInh = 1; 
 *Create variable for all drug use; 
 IF treatment = 1 OR PredTreat = 1 OR PredInh =1 THEN AllTherapy = 1; 
 ELSE IF treatment = '.' AND PredTreat = '.' AND PredInh ='.' THEN AllTherapy = '.'; 
 ELSE IF treatment = 0 AND PredTreat = 0 AND PredInh = 0 THEN AllTherapy = 0; 
 ELSE AllTherapy = '.'; 
*Change variables be to numeric; 
DLCOppN = INPUT (DLCOpp, 3.); 
treatmentN = INPUT (treatment, 1.); 
PredTreatN = INPUT (PredTreat, 1.); 
PredImmN = INPUT (PredImm, 1.); 
PredInhN = INPUT (PredInh, 1.); 
RaceN = INPUT (Race, 1.); 






*Wasfi score spiro; 
IF FEV1_FVCpp NE '.' AND Treatment NE '.' AND AArace NE '.' THEN DO; 
 WasfiSpiro = 11.46 + (3.9 * cardiac) + (2.56 * neuro) + (1.56 * treatmentN) - (0.051 
* FVCpp) - (0.054 * FEV1_FVCpp) + (1.75 * AArace); 
 END; 
ELSE WasfiSpiro = '.'; 
*Wasfi score dlco; 




 WasfiDLCO = 11.47 + (3.51 * cardiac) + (2.27 * neuro) + (1.41 * treatmentN) - 
(0.027 * FVCpp) - (0.047 * FEV1_FVCpp) + (1.23 * AArace) - (0.033 * DLCOppN) + 
(skin); 
 END; 
ELSE WasfiDLCO = '.'; 
*Hamzeh score; 
IF DLCOdata = 1 AND ScadStage NE '.' THEN DO; 
IF ScadStage = 0 OR ScadStage = 1 THEN HamScad = 0; 
IF ScadStage = 2 OR ScadStage = 3 THEN HamScad = 1; 
IF ScadStage = 4 THEN HamScad = 2; 
IF ScadStage = '.' THEN HamScad = '.'; 
IF DLCOppN GE 80 THEN HamDLCO = 0; 
IF DLCOppN LE 59 THEN HamDLCO = 2; 
IF DLCOppN = '.' THEN HamDLCO = '.'; 
ELSE HamDLCO = 1; 
IF FVCpp GE 80 THEN HamFVC = 0; 
IF FVCpp LE 59 THEN HamFVC = 2; 
IF FVCpp = '.' THEN HamFVC = '.'; 
ELSE HamFVC = 1; 
IF FEV1_FVCpp GE 70 THEN Hamfevfvc = 0; 
IF FEV1_FVCpp LT 70 THEN Hamfevfvc = 1; 
IF FEV1_FVCpp = '.' THEN Hamfevfvc = '.'; 
IF HamScad NE '.' AND HamDLCO NE '.' AND HamFVC NE '.' AND Hamfevfvc NE '.' 
THEN DO; 
Hamzeh = HamScad + HamDLCO + HamFVC + Hamfevfvc; 
END; 
ELSE Hamzeh = '.'; 
END; 





*Create variable for time since dx; 
IF BiopsyProven = 'yes' THEN DO; 
 IF BiopsyDate NE '.' AND StudyDate NE '.' THEN DO; 
  TimeSinceDx = INT(DATDIF(BiopsyDate, StudyDate, 'Actual')); 
  END; 
 ELSE TimeSinceDx = '.'; 
 END; 
ELSE TimeSinceDx = '.'; 
IF TimeSinceDx LT 0 THEN TimeDx = 0; 
ELSE TimeDx = TimeSinceDx; 
*Delete subjects with no lung involvement; 
IF Lungs = 0 THEN DELETE; 
*Make ethnicity numeric; 
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Create table check.combined as 
SELECT *  
FROM check.hamzeh natural join check.wasfidlco; 
 
*Recategorize PSSI score; 
DATA check.combined2; 
SET check.combined; 
IF Hamzeh = 5 THEN Hamzeh2 = 4; 
ELSE Hamzeh2 = Hamzeh; 
RUN; 
 
*log transform regression eq; 
DATA check.transform1; 
SET check.wasfispiro; 




/*Code for calculating time-dependent variables in the Full sample.*/ 
DATA final.everything; 






*Assign useable date for everyone; 
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IF StudyDate = '.' THEN PrimaryDate = EnrollmentDate; 
ELSE IF StudyDate NE '.' THEN PrimaryDate = StudyDate; 
*Create age variable; 
IF Age = '.' THEN DO; 
 IF PrimaryDate NE '.' THEN DO; 
  PrimaryAge = INT(YRDIF(DOB, PrimaryDate, 'Actual')); 
  END; 
 ELSE PrimaryAge = '.'; 
 END; 
ELSE PrimaryAge = Age; 
*Create variable to indicate all drug use; 
*Create variable to indicate recent medication use...using the fact that I filled the blank slots 
in order.  If there is not 2nd drug, there is no 3rd drug; 
IF PrimaryDate NE '.' THEN DO; 
 IF d2ndDrug = ' ' THEN RecTreat2p = '0'; 
 IF d2ndDrug NE ' ' THEN DO; 
 IF d2ndDrugStarted NE '.' THEN DO; 
 *If study date is before the start of the drug, then no treatment; 
 IF d2ndDrugStarted GE PrimaryDate THEN RecTreat2p = '0'; 
 *If study date is between start and stop dates, then there is treatment; 
 IF d2ndDrugStarted LT PrimaryDate AND d2ndDrugStopped = '.' THEN RecTreat2p 
= '1'; 
 IF d2ndDrugStarted LT PrimaryDate AND d2ndDrugStopped GE PrimaryDate 
THEN RecTreat2p = '1'; 
 *If study date is after stop date, then it is time dependent; 
 IF d2ndDrugStopped NE '.' AND d2ndDrugStopped LT PrimaryDate THEN DO; 
  TreatDiff2p = INT(DATDIF(d2ndDrugStopped, PrimaryDate, 'ACT/ACT')); 
  IF TreatDiff2p NE '.' AND TreatDiff2p LE 30 THEN RecTreat2p = '1'; 
  ELSE IF TreatDiff2p NE '.' THEN RecTreat2p = '0'; 




ELSE RecTreat2p = ' '; 
*Create variable to indicate recent medication use...using the fact that I filled the blank slots 
in order.  If there is not 2nd drug, there is no 3rd drug; 
IF PrimaryDate NE '.' THEN DO; 
 IF d3rdDrug = ' ' THEN RecTreat3p = '0'; 
 IF d3rdDrug NE ' ' THEN DO; 
 IF d3rdDrugStarted NE '.' THEN DO; 
 *If study date is before the start of the drug, then no treatment; 
 IF d3rdDrugStarted GE PrimaryDate THEN RecTreat3p = '0'; 
 *If study date is between start and stop dates, then there is treatment; 




 IF d3rdDrugStarted LT PrimaryDate AND d3rdDrugStopped GE PrimaryDate THEN 
RecTreat3p = '1'; 
 *If study date is after stop date, then it is time dependent; 
 IF d3rdDrugStopped NE '.' AND d3rdDrugStopped LT PrimaryDate THEN DO; 
  TreatDiff3p = INT(DATDIF(d3rdDrugStopped, PrimaryDate, 'ACT/ACT')); 
  IF TreatDiff3p NE '.' AND TreatDiff3p LE 30 THEN RecTreat3p = '1'; 
  ELSE IF TreatDiff3p NE '.' THEN RecTreat3p = '0'; 




ELSE RecTreat3p = ' '; 
 *Determine non-corticoidsteroid medication use; 
 IF RecTreat2p = ' ' AND RecTreat3p = ' ' THEN treatmentp = '.'; 
 ELSE IF RecTreat2p = '1' OR RecTreat3p = '1' THEN treatmentp = 1; 
 ELSE IF RecTreat2p = '0' AND RecTreat3p = ' ' THEN treatmentp = 0;  





*Create variable to indicate recent prednisone use...using the fact that I filled the blank slots 
in order.  If there is not 2nd drug, there is no 3rd drug; 
IF PrimaryDate NE '.' THEN DO; 
 IF Prednisone = ' ' THEN RecPredp = ' '; 
 IF Prednisone = 'no' THEN RecPredp = '0'; 
 IF Prednisone EQ 'yes' THEN DO; 
 IF PredStarted NE '.' THEN DO; 
 *If study date is before the start of the drug, then no treatment; 
 IF PredStarted GE PrimaryDate THEN RecPredp = '0'; 
 *If study date is between start and stop dates, then there is treatment; 
 IF PredStarted LT PrimaryDate AND PredStopped = '.' THEN RecPredp = '1'; 
 IF PredStarted LT PrimaryDate AND PredStopped GE PrimaryDate THEN RecPredp 
= '1'; 
 *If study date is after stop date, then it is time dependent; 
 IF PredStopped NE '.' AND PredStopped LT PrimaryDate THEN DO; 
  PredDiffp = INT(DATDIF(PredStopped, PrimaryDate, 'ACT/ACT')); 
  IF PredDiffp NE '.' AND PredDiffp LE 30 THEN RecPredp = '1'; 
  ELSE IF PredDiffp NE '.' THEN RecPredp = '0'; 




ELSE RecPredp = ' '; 
 *Create numeric variable for pred used; 
 IF RecPredp = ' ' THEN PredTreatp = '.'; 
60 
 
 IF RecPredp = '0' THEN PredTreatp = 0; 
 IF RecPredp = '1' THEN PredTreatp = 1; 
 *Create variable for pred and immmunosupp use; 
 IF treatmentp = '.' AND PredTreatp = '.' THEN PredImmp = '.'; 
 ELSE IF treatmentp = 1 OR PredTreatp = 1 THEN PredImmp = 1; 
 ELSE IF treatmentp = 0 AND PredTreatp = '.' THEN PredImmp = '.';  
 ELSE IF treatmentp = '.' AND PredTreatp = 0 THEN PredImmp = 0;  
 ELSE IF treatmentp = 0 AND PredTreatp = 0 THEN PredImmp = 0; 
 *Create variable for pred and inhaled used; 
 IF PredTreatp = '.' AND InhaledSteroid = ' ' THEN PredInhp = '.'; 
 IF PredTreatp = 0 AND InhaledSteroid = ' ' THEN PredInhp = 0; 
 IF PredTreatp = 0 AND InhaledSteroid NE ' ' THEN PredInhp = 1; 
 IF PredTreatp = 1 AND InhaledSteroid = ' ' THEN PredInhp = 1; 
 IF PredTreatp = 1 AND InhaledSteroid NE ' ' THEN PredInhp = 1; 
 *Create variable for all drug use; 
 IF treatmentp = 1 OR PredTreatp = 1 OR PredInhp =1 THEN AllTherapyp = 1; 
 ELSE IF treatmentp = '.' AND PredTreatp = '.' AND PredInhp ='.' THEN 
AllTherapyp = '.'; 
 ELSE IF treatmentp = 0 AND PredTreatp = 0 AND PredInhp = 0 THEN AllTherapyp 
= 0; 






*Change DLCOpp to numeric variable; 
DLCOppN = INPUT (DLCOpp, 3.); 
treatmentN = INPUT (treatment, 1.); 
PredTreatN = INPUT (PredTreat, 1.); 
PredImmN = INPUT (PredImm, 1.); 
PredInhN = INPUT (PredInh, 1.); 
RaceN = INPUT (Race, 1.); 
GenderN = INPUT (Gender, 1.); 
*Create variable for time since dx; 
IF BiopsyProven = 'yes' THEN DO; 
 IF BiopsyDate NE '.' AND PrimaryDate NE '.' THEN DO; 
  TimeSinceDx = INT(DATDIF(BiopsyDate, PrimaryDate, 'Actual')); 
  END; 
 ELSE TimeSinceDx = '.'; 
 END; 
ELSE TimeSinceDx = '.'; 
IF TimeSinceDx LT 0 THEN TimeDx = 0; 
ELSE TimeDx = TimeSinceDx; 
RUN; 
 
